Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 15, 2006CirculationOpen Access

Biomarkers of Cardiovascular Disease

View Full Paper
Ask AI
Bookmark
Share

Design

Review

Authors

Ramachandran S. VasanRamachandran S. VasanGeneral / Preventive / Lipids

Discussion

Loading...

Member takes

Implication

Biomarker use in cardiovascular disease should remain cautious pending validation; this synthesis leaves open rigorous prospective testing for clinical adoption.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ramachandran S. Vasan (2006) studied this question.

synapsesocial.com/papers/69eff959bce9831ba4f73681https://doi.org/10.1161/circulationaha.104.482570
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Current Concepts of "Normal Values," "Reference Values," and "Discrimination Values" in Clinical Chemistry1975 · 151 citations
  2. 2Homocysteine and Risk of Ischemic Heart Disease and Stroke2002 · 2,079 citations
  3. 3Updated New Zealand cardiovascular disease risk-benefit prediction guide2000 · 229 citations
  4. 4Nuclear Magnetic Resonance Spectroscopy of Lipoproteins and Risk of Coronary Heart Disease in the Cardiovascular Health Study2002 · 313 citations
  5. 5Association Between Myeloperoxidase Levels and Risk of Coronary Artery Disease2001 · 927 citations